In contrast, tumour response to PD-1 inhibitors was found to be consistent across PD-L1 positive and negative MSI-H/dMMR tumours in the KEYNOTE-016 and CheckMate 142 studies [22, 30]. The gene discussed is CD274; the disease is neoplasm.